Old Web
English
Sign In
Acemap
>
authorDetail
>
Selina Moy
Selina Moy
Astellas Pharma
Pharmacokinetics
Medicine
Pharmacology
Adverse effect
QT interval
4
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
2021
Clinical Pharmacokinectics
Angela Joubert James
Catherine C. Smith
Mark R. Litzow
Alexander E. Perl
Jessica K. Altman
Dale R. Shepard
Takeshi Kadokura
Kinya Souda
Melanie Patton
Zheng Lu
Chaofeng Liu
Selina Moy
Mark J. Levis
Erkut Bahceci
Show All
Source
Cite
Save
Citations (1)
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
2020
Clinical Pharmacokinectics
Angela Joubert James
Catherine C. Smith
Mark R. Litzow
Alexander E. Perl
Jessica K. Altman
Dale R. Shepard
Takeshi Kadokura
Kinya Souda
Melanie Patton
Zheng Lu
Chaofeng Liu
Selina Moy
Mark J. Levis
Erkut Bahceci
Show All
Source
Cite
Save
Citations (11)
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
2020
Clinical Drug Investigation
Tong Zhu
Selina Moy
U. Valluri
Ying Cao
Wenhui Zhang
Taiji Sawamoto
Vishala Chindalore
Bola Akinlade
Show All
Source
Cite
Save
Citations (3)
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females
2016
Drug Metabolism and Pharmacokinetics
Yuki Nomura
Hiromi Iitsuka
Junko Toyoshima
Kentaro Kuroishi
Toshifumi Hatta
Atsunori Kaibara
Masataka Katashima
Selina Moy
Taiji Sawamoto
Show All
Source
Cite
Save
Citations (4)
1